Sotera Health (NASDAQ:SHC) Shares Sold by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. lessened its holdings in Sotera Health (NASDAQ:SHC - Free Report) by 19.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,594,741 shares of the company's stock after selling 1,823,250 shares during the period. T. Rowe Price Investment Management Inc. owned about 2.68% of Sotera Health worth $103,897,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Xponance Inc. grew its holdings in Sotera Health by 6.0% during the 4th quarter. Xponance Inc. now owns 17,495 shares of the company's stock valued at $239,000 after purchasing an additional 989 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Sotera Health by 2.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,940 shares of the company's stock valued at $711,000 after acquiring an additional 1,047 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Sotera Health by 37.5% during the fourth quarter. GAMMA Investing LLC now owns 4,109 shares of the company's stock worth $56,000 after acquiring an additional 1,121 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Sotera Health by 164.3% in the fourth quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock worth $25,000 after acquiring an additional 1,140 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Sotera Health by 37.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company's stock valued at $82,000 after purchasing an additional 1,640 shares during the last quarter. Institutional investors and hedge funds own 91.03% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SHC. Piper Sandler cut their target price on Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Barclays reduced their price objective on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.20.

Sotera Health Stock Performance

Shares of SHC traded down $0.08 during mid-day trading on Wednesday, hitting $11.23. The stock had a trading volume of 211,830 shares, compared to its average volume of 1,200,623. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The company has a market cap of $3.19 billion, a PE ratio of 44.92 and a beta of 1.88. Sotera Health has a fifty-two week low of $9.53 and a fifty-two week high of $17.08. The company's fifty day simple moving average is $11.47 and its two-hundred day simple moving average is $13.10.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.